Candel Therapeutics is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Co. has oncolytic viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Co.'s product candidate, CAN-2409, is an off-the-shelf adenovirus product candidate combined with the prodrug valacyclovir. Co. is conducting, as part of its CAN-2409 program, a clinical trial in the U.S. for CAN-2409 in patients with newly diagnosed localized prostate cancer who have an intermediate- or high-risk for progression. Co. is also developing its HSV platform product candidates for solid tumor indications. The CADL average annual return since 2021 is shown above.
The Average Annual Return on the CADL average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CADL average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CADL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|